Yoshiaki Nakamura, MD

Nationwide Circulating-Tumor DNA–Guided Basket and Umbrella Clinical Trials for Patients With Advanced Solid Tumors (GOZILA; UMIN000029315)

Circulating tumor DNA (ctDNA)-based next- generation sequencing (NGS) assays have advantages over classic tissue-based analyses because of their low invasiveness and availability of repeated sampling. The existence of various companion trials for common alterations that can be potential therapy targets on the 2 platforms can lead to future international collaboration.